CAS: 1801344-14-8; (R)-N-(5-(3-Hydroxypyrrolidin-1-yl)-2-Morpholinooxazolo[4,5-B]Pyridin-6-yl)-2-(2-Methylpyridin-4-yl)Oxazole-4-Carboxamide
该化合物是一个复杂的有机化合物,其特点是多周期结构和各种功能组的存在,该物质具有牛角环,有助于其杂交性,并包括一种加强潜在生物活动的环状动物,在双龙环上存在一个氢氧化物组,表明氢联结的潜力,这可能影响其溶性以及与生物目标的相互作用;此外,低温组可能提供灵活性和消毒效应,可能影响化合物的药理和药理动力学;总体而言,该化合物有可能显示与生物系统的具体互动,使其对医药化学和药物开发感兴趣,特别是在针对某些受体或酶的情况下,其详细特性,包括溶性,稳定性和再活性,需要进一步的经验调查.
- 英文名称(R)-N-(5-(3-Hydroxypyrrolidin-1-yl)-2-Morpholinooxazolo[4,5-B]Pyridin-6-yl)-2-(2-Methylpyridin-4-yl)Oxazole-4-Carboxamide
- 中文名称(R)-N-(5-(3-羟基吡咯烷-1-基)-2-吗啉代噁唑[4,5-B]吡啶-6-基)-2-(2-甲基吡啶-4-基)恶唑-4-甲酰胺
- IUPAC名称(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide
- CAS编号1801344-14-8
- MFCD编号:MFCD32693907
- FDA UNII编号:MH5DMF9JKY
- 分子式:C24H25N7O5分子量:491.51
- 产品CID: 927964
- 同类组份化合物CAS2376399-39-0 (maleate)1801344-14-8 (free base)2376399-42-5 (HCl)1801343-74-7 (CA4948-Analog)2376399-40-3(mesylate)2376399-41-4 (tosylate)2376399-38-9 (phosphate)
- 产品分类Chemistry → Heterocyclic Building Blocks → Aromatic Heterocycles | JAK/STAT Signaling → FLT3 | Inhibitors/Agonists → Immunology/Inflammation → IRAK | Inhibitors/Agonists → Immunology/Inflammation → MyD88
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2905122000-异丙醇
2909110000-乙醚
2912110000-甲醛
2922110001-单乙醇胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Xu J, Qian Q, Xia M, Wang X, Wang H. Trichlorocarban induces developmental and immune toxicity to zebrafish (Danio rerio) by targeting TLR4/MyD88/NF-κB signaling pathway. Environ Pollut. 2021 Jan 10;273:116479. doi: 10.1016/j.envpol.2021.116479. Epub ahead of print. 11(12):2374-2381. doi: 10.1021/acsmedchemlett.0c00255.
3: Wiese MD, Manning-Bennett AT, Abuhelwa AY. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 May;29(5):475-482. doi: 10.1080/13543784.2020.1752660. Epub 2020 Apr 17. 29(4):243-259. doi: 10.1080/13543776.2019.1597850. Epub 2019 Mar 29.
合成参考文献
参考文献:10.1021/acs.jmedchem.4c00202
摘要:Zou Y, Wang X, Chen P, Zheng Z, Li X, Chen Z, Guo M, Zhou Y, Sun C, Wang R, Zhu W, Zheng P, Cho WJ, Cho YC, Liang G, Tang Q. Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury. J Med Chem. 2024 Jul 11;67(13):10687–709. doi: 10.1021/acs.jmedchem.4c00202.
📝 需求与反馈
尽可能描述清楚需求与问题信息
